TrialArthritis & rheumatology (Hoboken, N.J.)2026

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial.

Hermine I Brunner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.